ALX Oncology’s evorpacept shows promise in HER2-positive breast cancer
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
Subscribe To Our Newsletter & Stay Updated